- COVID-19
- Biosimilars
- Cataract Therapeutics
- DME
- Gene Therapy
- Workplace
- Ptosis
- Optic Relief
- Imaging
- Geographic Atrophy
- AMD
- Presbyopia
- Ocular Surface Disease
- Practice Management
- Pediatrics
- Surgery
- Therapeutics
- Optometry
- Retina
- Cataract
- Pharmacy
- IOL
- Dry Eye
- Understanding Antibiotic Resistance
- Refractive
- Cornea
- Glaucoma
- OCT
- Ocular Allergy
- Clinical Diagnosis
- Technology
About Our Sponsor: VIGAMOX™ (moxifloxacin HCl ophthalmic solution)
VIGAMOX™ (moxifloxacin HCl ophthalmic solution) 0.5% as base is theonly FDA-approved fluoroquinolone drop that offers the following featuresand benefits: VIGAMOX™ solution is the only fourth generation fluoroquinolone eye-drop formulated at a 0.5% concentration, providing higher drug concentration throughout the relevant ocular structures.1 Formulated at a pH of 6.8, the near-neutral pH of VIGAMOX™ solution translates directly into excellent comfort, tolerability and increased solubility.1 VIGAMOX™ solution is robust enough to not only meet, but exceed all United States Pharmacopoeia (USP) tests without the need for benzalkonium chloride: this is a direct result of the inherent anti-bacterial andanti-fungal activity of the moxifloxacin formulation itself.2 The active ingredient of VIGAMOX™, solution moxifloxacin, is the only available fluoroquinolone with a bicyclic side-chain at the C-7 position: this reduces the ability of the microbial cell's efflux pump to flush out antibiotic, thus increasing the drug's length of stay in the microorganism, leading to improved efficacy and further inhibition of resistance.1 These unique product attributes speak directly to the benefits that VIGAMOX™ solution brings to ophthalmologists and patients. Please see prescribinginformation at www.vigamox.com.1Alfonso EC, Katz HR, McCulley JP, O'Brien TP. Moxifloxacin 0.5%: a4th generation ocular fluoroquinolone. Excerpts from RefractiveEyecare for Ophthalmologists. March 2003; 7 (suppl):202Moxifloxacin: Antimicrobial efficacy test results. Data on file, AlconLaboratories, Inc.
